January 26, 2023
White House officials this week announced the end of the “X-Waiver,” a move they say will remove barriers to treatment for patients with opioid use disorder.
During an event on Tuesday, White house and federal officials celebrated the end of the DATA-Waiver Program, also known as the X-Waiver requirement. The change allows physicians to prescribe buprenorphine for opioid use disorder—as long as they have their standard registration with the Drug Enforcement Administration (DEA).
“At a time when our nation has experienced 107,000 drug overdose and poisonings in just one year’s time, this change could not have come sooner,” said Dr. Rahul Gupta, director of the White House Office of National Drug Control Policy.
Here’s what you need to know:
HAP and Pennsylvania’s hospitals remain committed to advancing treatment and access for substance use disorder and behavioral health care. This includes supporting patients through evidence-based treatment and initiatives to reduce overdose deaths.
Tags: Public Health | Substance Use Disorder | Behavioral Health
Click on topic below for category-specific news articles.
Related Links
Support a healthier Pennsylvania.